- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01665911
An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy
3. února 2015 aktualizováno: Frank Lippert
The study will be randomized, investigator-blind, observer-blind, laboratory analyst-blind and will utilize a 5-way cross-over study design with a primary objective to determine if a higher dose of fluoride in milk will provide a greater caries preventive effect.
Secondary objectives are to determine in a higher concentration of fluoride in milk will provide a greater caries preventive effect and if the caries preventive effect of fluoridated milk follows a dose-response pattern.
Přehled studie
Postavení
Dokončeno
Podmínky
Detailní popis
The evidence of milk fluoridation as a public health measure in caries prevention has been demonstrated in many clinical studies.
While these data are encouraging, the main focus now should be on the optimization of milk fluoride programs.
This protocol will concentrate on the parameters of fluoride dose and concentration utilizing an in situ model, the intra-oral caries test or model (ICT).
The ICT is an established model which features the use of gauze-covered specimens to facilitate plaque growth and to simulate a caries-prone/plaque stagnation area.
After subject has been consented and enrolled in the study per the inclusion/exclusion criteria, two to three days following a dental cleaning, two partially demineralized specimens will be placed in the buccal flange area of the subject's mandibular partial denture.
During each of the five, three-week test periods, subjects will drink their assigned milk test product once per day for either five (100 ml milk) or ten (200 ml milk) timed minutes, wearing their mandibular partial dentures 24 hours a day during the test period.
Fluoride free toothpaste will be used two to three days before and continuously during each treatment period.
After each three-week test period, the two partially demineralized specimens will be removed from the subject's partial denture and analyzed using the surface microhardness test.
Mineral content change (as percentage of surface microhardness recovery) in these artificially induced incipient enamel lesions will be the primary outcome variable.
Each subject (n = 28) will serve as his or her own control.
Typ studie
Intervenční
Zápis (Aktuální)
28
Fáze
- Nelze použít
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Oral Health Research Institute, Indiana University School of Dentistry
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let až 80 let (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ano
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- sign an informed consent, authorization for the release of health information for research and provide medical history information, including medications, prior to their participation;
- be between 18 and 80 years old and in general good health;
- willingness to use a reliable form of contraception or abstaining during the course of the study (females of child-bearing potential only)
- wear a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12×7 mm);
- be willing and capable of wearing their removable mandibular partial dentures 24 hours a day for a total of five, three-week test periods;
- be in good dental health with no active caries or periodontal disease;
- agree to comply with all subjects' responsibilities as stated in the protocol (e.g. use of study products, attendance at appointments, etc.);
- have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 ml/min; gum base stimulated whole saliva flow rate ≥ 0.8 ml/min).
- Be able to tolerate the taste and room temperature of the mixed milk product as demonstrated by drinking the milk at screening
Exclusion Criteria:
be pregnant, intending to become pregnant during the study period or breast feeding. A urine pregnancy test will be required at screening, the start of each treatment visit and the last study visit for all subjects of child-bearing potential to confirm the subject is not pregnant.
- have any medical condition that could be expected to interfere with the subject's safety during the study period;
- demonstrate an inability to comply with study procedures;
- have factors which could contraindicate their participation, such as any condition requiring the need for antibiotic premedication prior to a dental treatment, a condition requiring the need for long-term antibiotic use, blood thinning medications that prohibit the safe conduct of a dental cleaning* or previous use of the weight loss medications Fen Phen® or Redux®. (*Note: Subjects who are taking blood thinners in which written verification is obtained from their physician indicating their PT/INR levels (anti-coagulation blood levels) are at an acceptable level to avoid serious complications, such as bleeding during dental cleanings, may be accepted into the study at the discretion of the Investigator.)
- be currently taking or have ever taken a bisphosphonate drug (i.e. Fosamax®, Actonel®, Boniva®, Reclast®, or Zometa®) for treatment of osteoporosis.
- be lactose intolerant or have known allergy or intolerance to milk or milk products
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Jiný: Arm 1
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
|
|
Jiný: Arm 2
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
|
|
Jiný: Arm 3
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
|
|
Jiný: Arm 4
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
|
|
Aktivní komparátor: Arm 5
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
|
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design
Ostatní jména:
Each subject will use this product during one of the five treatment periods in the crossover study design.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
% Surface Microhardness (SMH) Recovery Score Per Each of Five Arms
Časové okno: Three Weeks per each of five arms
|
|
Three Weeks per each of five arms
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
% Acid Resistance Score Per Each of Five Arms
Časové okno: Three Weeks per each of five arms
|
% Acid Resistance is a measure of acid resistance of the remineralized caries lesion which is calculated as (D1-D2)/(D1-B)*100%, where B is the indentation length of sound enamel specimen at baseline, D1 is an indentation length after first in vitro demineralization, D2 is an indentation length after second in vitro demineralization.
|
Three Weeks per each of five arms
|
|
Enamel Fluoride Uptake Per Each of Five Arms
Časové okno: Three Weeks per each of five arms
|
Enamel fluoride uptake is a measure of fluoridation of a caries lesion
|
Three Weeks per each of five arms
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Domenick Zero, DDS, MS, Indiana University
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. srpna 2012
Primární dokončení (Aktuální)
1. dubna 2013
Dokončení studie (Aktuální)
1. června 2013
Termíny zápisu do studia
První předloženo
7. srpna 2012
První předloženo, které splnilo kritéria kontroly kvality
13. srpna 2012
První zveřejněno (Odhad)
16. srpna 2012
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
23. února 2015
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
3. února 2015
Naposledy ověřeno
1. února 2015
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 12-I-086
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .